Recently, a class of small peptides that target the PDID phospho‐region on BET was developed.43 Although these peptoids are not yet developed for clinical application because of their low affinity for target proteins, they offer a unique strategy to develop approaches for BET inhibition of genes binding specifically to the BRD4 PDID, which will benefit patients with either BRD4‐hyperphosphorylated triple‐negative breast cancer44 or GLTSCR1‐mutated CRC as adjuvant chemotherapy in the future. Here, BRD4 is linked to colorectal carcinoma.